{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Deloria Knoll M"],"funding":["Bill and Melinda Gates Foundation"],"pagination":["742"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8066045"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(4)"],"pubmed_abstract":["Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 "],"journal":["Microorganisms"],"pubmed_title":["Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project."],"pmcid":["PMC8066045"],"funding_grant_id":["INV-010429 / OPP1189065"],"pubmed_authors":["Leon ME","Mungun T","De Wals P","Hetrich MK","Peterson ME","Savulescu C","Dagan R","Camilli R","Ciruela P","Sinkovec Zorko N","Bigogo G","Oishi K","Saha SK","Mad'arova L","Chan G","Georgakopoulou T","Paragi M","Setchanova LP","Mackenzie GA","Danis K","Kristinsson KG","Chanto Chacon G","van der Linden M","Yildirim I","Kagucia EW","Yang Y","Cook H","Scott JA","Nuorti JP","Bennett JC","Lepp T","Ho PL","Savrasova L","Kozakova J","Galloway Y","Nzoyikorera N","Feikin DR","Kellner JD","Ladhani SN","Hilty M","Mwenda JM","Desmet S","Castilla J","Hammitt LL","Jayasinghe S","Rafai E","Vestrheim DF","von Gottberg A","Cohen AL","Kleynhans J","Skoczynska A","Garcia Quesada M","Aukes L","Lara CS","Ampofo K","Hayford K","Deloria Knoll M","McGeer A","de Miguel S","Corcoran M","Knol MJ","Sinkevitch JN","Pilishvili T","Scott KJ","Puentes R","Bruce MG","De Oliveira LH","Valentiner-Branth P","The Pserenade Team","Brandileone MC","Serhan F","Bacci S","Swarthout TD"],"additional_accession":[]},"is_claimable":false,"name":"Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project.","description":"Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-07T05:15:12.513Z","creation":"2025-04-07T05:15:12.513Z"},"accession":"S-EPMC8066045","cross_references":{"pubmed":["33918127"],"doi":["10.3390/microorganisms9040742"]}}